Actinic (Solar) Keratosis - Pipeline Review, H2 2016

Actinic (Solar) Keratosis - Pipeline Review, H2 2016


  • Products Id :- GMDHC8452IDB
  • |
  • Pages: 75
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Actinic (Solar) Keratosis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Actinic (Solar) Keratosis - Pipeline Review, H2 2016', provides an overview of the Actinic (Solar) Keratosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis

- The report reviews pipeline therapeutics for Actinic (Solar) Keratosis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Actinic (Solar) Keratosis therapeutics and enlists all their major and minor projects

- The report assesses Actinic (Solar) Keratosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Actinic (Solar) Keratosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Actinic (Solar) Keratosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Actinic (Solar) Keratosis Overview 9

Therapeutics Development 10

Pipeline Products for Actinic (Solar) Keratosis - Overview 10

Pipeline Products for Actinic (Solar) Keratosis - Comparative Analysis 11

Actinic (Solar) Keratosis - Therapeutics under Development by Companies 12

Actinic (Solar) Keratosis - Therapeutics under Investigation by Universities/Institutes 13

Actinic (Solar) Keratosis - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Unknown Stage Products 17

Actinic (Solar) Keratosis - Products under Development by Companies 18

Actinic (Solar) Keratosis - Products under Investigation by Universities/Institutes 19

Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development 20

3M Drug Delivery Systems 20

Athenex, Inc. 21

Digna Biotech, S.L. 22

Foamix Pharmaceuticals Ltd. 23

G&E Herbal Biotechnology Co., Ltd. 24

Galderma S.A. 25

Laboratories Ojer Pharma S.L. 26

LEO Pharma A/S 27

Novartis AG 28

Oncology Research International Limited 29

Promius Pharma, LLC 30

Spherium Biomed S.L. 31

Valeant Pharmaceuticals International, Inc. 32

Vectura Group Plc 33

Actinic (Solar) Keratosis - Therapeutics Assessment 34

Assessment by Monotherapy Products 34

Assessment by Combination Products 35

Assessment by Target 36

Assessment by Mechanism of Action 38

Assessment by Route of Administration 40

Assessment by Molecule Type 42

Drug Profiles 44

854-A - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

ACT-01 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

AD-17137 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

celecoxib - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

DFD-08 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

disitertide - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

hydrogen peroxide + sulindac - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

IDP-125 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

IDP-128 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

imiquimod - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

imiquimod SR - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

KX-01 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

LEO-43204 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

LFX-453 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

ORIL-007 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Recombinant Peptide for Dermatology, Immunology and Oncology - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

resiquimod - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

SKP-024 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Small Molecules to Activate Protein Kinase C for Actinic Keratosis and Non-melanoma Skin Cancer - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

SP-12054 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

SRT-100 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

VDA-1102 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

VPE-001 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Actinic (Solar) Keratosis - Dormant Projects 70

Actinic (Solar) Keratosis - Discontinued Products 72

Actinic (Solar) Keratosis - Product Development Milestones 73

Featured News & Press Releases 73

Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study 73

Appendix 74

Methodology 74

Coverage 74

Secondary Research 74

Primary Research 74

Expert Panel Validation 74

Contact Us 74

Disclaimer 75

List of Figures

Number of Products under Development for Actinic (Solar) Keratosis, H2 2016 10

Number of Products under Development for Actinic (Solar) Keratosis - Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy Products, H2 2016 34

Number of Products by Top 10 Targets, H2 2016 36

Number of Products by Stage and Top 10 Targets, H2 2016 36

Number of Products by Top 10 Mechanism of Actions, H2 2016 38

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 38

Number of Products by Routes of Administration, H2 2016 40

Number of Products by Stage and Routes of Administration, H2 2016 40

Number of Products by Molecule Types, H2 2016 42

Number of Products by Stage and Molecule Types, H2 2016 42

List of Tables

Number of Products under Development for Actinic (Solar) Keratosis, H2 2016 10

Number of Products under Development for Actinic (Solar) Keratosis - Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 15

Comparative Analysis by Early Stage Development, H2 2016 16

Comparative Analysis by Unknown Stage Development, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Investigation by Universities/Institutes, H2 2016 19

Actinic (Solar) Keratosis - Pipeline by 3M Drug Delivery Systems, H2 2016 20

Actinic (Solar) Keratosis - Pipeline by Athenex, Inc., H2 2016 21

Actinic (Solar) Keratosis - Pipeline by Digna Biotech, S.L., H2 2016 22

Actinic (Solar) Keratosis - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 23

Actinic (Solar) Keratosis - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2016 24

Actinic (Solar) Keratosis - Pipeline by Galderma S.A., H2 2016 25

Actinic (Solar) Keratosis - Pipeline by Laboratories Ojer Pharma S.L., H2 2016 26

Actinic (Solar) Keratosis - Pipeline by LEO Pharma A/S, H2 2016 27

Actinic (Solar) Keratosis - Pipeline by Novartis AG, H2 2016 28

Actinic (Solar) Keratosis - Pipeline by Oncology Research International Limited, H2 2016 29

Actinic (Solar) Keratosis - Pipeline by Promius Pharma, LLC, H2 2016 30

Actinic (Solar) Keratosis - Pipeline by Spherium Biomed S.L., H2 2016 31

Actinic (Solar) Keratosis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 32

Actinic (Solar) Keratosis - Pipeline by Vectura Group Plc, H2 2016 33

Assessment by Monotherapy Products, H2 2016 34

Assessment by Combination Products, H2 2016 35

Number of Products by Stage and Target, H2 2016 37

Number of Products by Stage and Mechanism of Action, H2 2016 39

Number of Products by Stage and Route of Administration, H2 2016 41

Number of Products by Stage and Molecule Type, H2 2016 43

Actinic (Solar) Keratosis - Dormant Projects, H2 2016 70

Actinic (Solar) Keratosis - Dormant Projects (Contd..1), H2 2016 71

Actinic (Solar) Keratosis - Discontinued Products, H2 2016 72

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3M Drug Delivery Systems

Athenex, Inc.

Digna Biotech, S.L.

Foamix Pharmaceuticals Ltd.

G&E Herbal Biotechnology Co., Ltd.

Galderma S.A.

Laboratories Ojer Pharma S.L.

LEO Pharma A/S

Novartis AG

Oncology Research International Limited

Promius Pharma, LLC

Spherium Biomed S.L.

Valeant Pharmaceuticals International, Inc.

Vectura Group Plc

Actinic (Solar) Keratosis Therapeutic Products under Development, Key Players in Actinic (Solar) Keratosis Therapeutics, Actinic (Solar) Keratosis Pipeline Overview, Actinic (Solar) Keratosis Pipeline, Actinic (Solar) Keratosis Pipeline Assessment

select a license

Single User License
USD 2000 INR 128720
Site License
USD 4000 INR 257440
Corporate User License
USD 6000 INR 386160

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com